Quality of life in the LRF CLL4 trial.

Quality of life in the LRF CLL4 trial.

Bibliographic Details
Main Authors:	Else, M, Smith, A, Hawkins, K, Crofts, S, Course, M, Richards, S, Catovsky, D
Format:	Conference item
Published:	2005

Similar Items

Quality of life in the UK LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
by: Else, M, et al.
Published: (2006)

Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.
by: Else, M, et al.
Published: (2012)

Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial.
by: Else, M, et al.
Published: (2008)

The lack of survival differences in randomised trials in CLL may be related to the effect of second line therapies. A report from the LRF CLL4 trial.
by: Catovsky, D, et al.
Published: (2006)

Comparison of oral and intravenous fludarabine in the LRF CLL4 trial.
by: Hillmen, P, et al.
Published: (2005)

A comparison of oral and intravenous fludarabine in the LRF CLL4 trial (on behalf of the UKNCRI CLL trials group)
by: Hillmen, P, et al.
Published: (2006)

Prognostic factors in the UK LRF CLL4 trial
by: Oscier, D, et al.
Published: (2006)

Prognostic factors in the UK LRF CLL4 trial.
by: Oscier, D, et al.
Published: (2005)

Prognostic factors in the UK LRF CLL4 trial.
by: Oscier, D, et al.
Published: (2006)

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
by: Dearden, C, et al.
Published: (2011)

Early results from LRF CLL4: A UK multicenter randomized trial
by: Catovsky, D, et al.
Published: (2005)

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.
by: Oscier, D, et al.
Published: (2010)

Baseline characteristics associated with quality of life in CLL patients requiring therapy
by: Else, M, et al.
Published: (2007)

Response to therapy and survival in CLL is influenced by genetic markers. preliminary analysis from the LRF CLL4 trial.
by: Catovsky, D, et al.
Published: (2004)

The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.
by: Matutes, E, et al.
Published: (2013)

The use of individualized tumor response testing in treatment selection: Second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry
by: Matutes, E, et al.
Published: (2013)

The combination of fludarabine and cyclophosphamide has a beneficial effect on the incidence of hemolytic anemia in chronic lymphocytic leukemia. Results from the UK LRF CLL4 trial
by: Dearden, C, et al.
Published: (2007)

Drug sensitivity by TRAC (DISC) assay as a prognostic factor for patient response in untreated CLL: Results from the UK LRF CLL4 trial.
by: Bosanquet, A, et al.
Published: (2006)

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
by: Catovsky, D, et al.
Published: (2007)

Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
by: Catovsky, D, et al.
Published: (2006)

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
by: Gonzalez, D, et al.
Published: (2011)

Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
by: Lin, K, et al.
Published: (2012)

Incidence of hemolytic anemia after chemotherapy in the CLL4 trial. A possible protective role for fludarabine plus cyclophosphamide.
by: Catovsky, D, et al.
Published: (2004)

Preliminary results of the UK Medical Research Council trial in chronic lymphocytic leukaemia - CLL3
by: Catovsky, D, et al.
Published: (1998)

UK Medical Research Council CLL3 - A randomized trial of the addition of epirubicin to standard chlorambucil treatment.
by: Catovsky, D, et al.
Published: (2000)

Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis.
by: Sellick, G, et al.
Published: (2008)

Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults.
by: Catovsky, D, et al.
Published: (1989)

Collaborative meta-analysis of randomised trials in chronic lymphocytic leukaemia (CLL)
by: Binet, J, et al.
Published: (1998)

isr-fctuc_lrf1_lrf2_cam_imu_carmen_dataset
by: Davim, Luis, et al.
Published: (2011)

Comparison of ZAP-70, IgVH gene mutational status and CD38 in CLL patients requiring therapy: Preliminary report from the UKCLL IV trial.
by: Orchard, J, et al.
Published: (2003)

Final results of a randomized trial comparing autotransplant versus wait and watch in 222 patients with CLL in 1(st) or 2(nd) remission (EBMT CLL auto trial / GCLLSG CLL3R trial)
by: McClanahan, F, et al.
Published: (2010)

Gender as a prognostic factor in CLL. Biological pointers to the improved outcome of women.
by: Catovsky, D, et al.
Published: (2004)

In vivo 'purging' of residual disease in CLL with Campath-1H.
by: Dyer, M, et al.
Published: (1997)

LRF assissted mapping and obstacle avoidance for hexapod robot Comet
by: Mohd Razali, Daud
Published: (2012)

The multi-faceted functioning portrait of LRF/ZBTB7A
by: Caterina Constantinou, et al.
Published: (2019-12-01)

Do not treat all CLL patients with fludarabine
by: Bosanquet, A, et al.
Published: (1998)

Results of the randomised phase II NCRI arctic (attenuated dose rituximab with chemotherapy in CLL) trial of low dose rituximab in previously untreated CLL
by: Munir, T, et al.
Published: (2014)

Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group.
by: Richards, S
Published: (1999)

Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion
by: Gonzalez, D, et al.
Published: (2008)

Lane Detection Algorithm Using LRF for Autonomous Navigation of Mobile Robot
by: Jong-Ho Han, et al.
Published: (2021-07-01)